New marker of platelet activation, SCUBE1, is elevated in hypertensive patients

Gülsüm Özkan1, Sukru Ulusoy, Ahmet Menteşe

  • 1Department of Nephrology, Karadeniz Technical University, School of Medicine, Trabzon, Turkey. gulsumozkan78@hotmail.com

Insights

Signal peptide-CUB-EGF domain-containing protein 1 (SCUBE1), a novel platelet activation marker, is elevated in hypertensive patients. This finding may aid in monitoring cardiovascular events in this population.

Area of Science:

  • Cardiovascular Medicine
  • Biochemistry
  • Hematology

Background:

  • Hypertension is linked to increased platelet activation and endothelial dysfunction, raising cardiovascular event risk.
  • Signal peptide-CUB-EGF domain-containing protein 1 (SCUBE1) is identified as a novel marker for platelet activation.
  • Limited research exists on SCUBE1 levels in hypertensive individuals.

Purpose of the Study:

  • To determine SCUBE1 levels in newly diagnosed, untreated stage 1 hypertensive patients.
  • To investigate factors influencing SCUBE1 levels in hypertension.
  • To explore SCUBE1 as a potential marker for cardiovascular events (CVEs).

Main Methods:

  • Compared 45 hypertensive patients with 21 healthy controls.
  • Measured SCUBE1, soluble CD40 ligand (sCD40L), and various biochemical markers including lipids and uric acid.
  • Analyzed the relationship between SCUBE1 levels and demographic/biochemical parameters.

Main Results:

  • SCUBE1 and sCD40L levels were significantly higher in hypertensive patients versus controls (P < 0.001; P < 0.05).
  • Hypertensive patients exhibited higher blood pressure, uric acid, LDL, total cholesterol, and triglyceride levels.
  • Systolic/diastolic BP, sCD40L, lipids, and uric acid levels correlated with SCUBE1 levels.

Conclusions:

  • Elevated SCUBE1 levels are demonstrated in primary hypertensive patients.
  • SCUBE1 shows potential as a novel marker for monitoring platelet activation and CVE risk in hypertension.
  • Further clinical studies are recommended to validate SCUBE1's utility in cardiovascular event prediction.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...